Company Overview and News

1
GGAL / Grupo Financiero Galicia S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-06-14 sec.gov
Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER
GGAL

0
GGAL / Grupo Financiero Galicia S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-05-30 sec.gov
Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER
GGAL

0
GGAL / Grupo Financiero Galicia S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-05-27 sec.gov
Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER
GGAL

1000
Tracking Dan Loeb's Third Point Portfolio - Q1 2018 Update

2018-05-22 seekingalpha
Dan Loeb's 13F portfolio value decreased from $13.86B to $13.32B this quarter. The number of positions decreased from 44 to 40.
PCG ATHTF STZ.B TWX CVS CRM SHW GGAL HON AABA AVGO DOW DOV MELI MAC AET MMM PBF GD TPRE WP KDMN UTX STZ BKI TWC BABA DVMT GOOGL MSFT APY MHK QCOM GRBK MGM FB DOV.WI LEN NXPI PAM PE NFLX PF GOOG BAX LEN.B MPC PAGS ADBE SPGI RSPP VMC MON ICE SWN HON EA WYNN LYB FTI.WI FMC ANTM DWDP BID NEXA BLK XRAY T SUPV DHR ANTX

3
GGAL / Grupo Financiero Galicia S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-05-15 sec.gov
Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER
GGAL

1
GGAL / Grupo Financiero Galicia S.A. AMENDMENT NO. 1 TO FORM 20-F

2018-05-09 sec.gov
Amendment no. 1 to Form 20-F AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 9, 2018 UNITED STATES
GGAL

1
GGAL / Grupo Financiero Galicia S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-05-03 sec.gov
Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER
GGAL

1
GGAL / Grupo Financiero Galicia S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-05-03 sec.gov
Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER
GGAL

1
GGAL / Grupo Financiero Galicia S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-04-26 sec.gov
Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER
GGAL

1
GGAL / Grupo Financiero Galicia S.A. FORM 20-F

2018-04-19 sec.gov
Form 20-F Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 19, 2018 UNITED STATES
GGAL

0
GGAL / Grupo Financiero Galicia S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-03-30 sec.gov
Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER
GGAL

0
GGAL / Grupo Financiero Galicia S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-03-30 sec.gov
Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER
GGAL

0
GGAL / Grupo Financiero Galicia S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-03-30 sec.gov
Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER
GGAL

0
GGAL / Grupo Financiero Galicia S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-03-22 sec.gov
Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
GGAL

0
GGAL / Grupo Financiero Galicia S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-03-14 sec.gov
Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
GGAL

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 399909100